- Home
- HITI vs ACIU Comparison
HITI vs ACIU Comparison
Compare HITI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HITI
- ACIU
- Stock Information
- Founded
- HITI 2009
- ACIU 2003
- Country
- HITI Canada
- ACIU Switzerland
- Employees
- HITI N/A
- ACIU N/A
- Industry
- HITI
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- HITI
- ACIU Health Care
- Exchange
- HITI Nasdaq
- ACIU Nasdaq
- Market Cap
- HITI 187.8M
- ACIU 168.7M
- IPO Year
- HITI N/A
- ACIU 2016
- Fundamental
- Price
- HITI $2.19
- ACIU $1.88
- Analyst Decision
- HITI Strong Buy
- ACIU Strong Buy
- Analyst Count
- HITI 2
- ACIU 1
- Target Price
- HITI $4.75
- ACIU $12.00
- AVG Volume (30 Days)
- HITI 293.1K
- ACIU 115.4K
- Earning Date
- HITI 06-16-2025
- ACIU 08-05-2025
- Dividend Yield
- HITI N/A
- ACIU N/A
- EPS Growth
- HITI N/A
- ACIU N/A
- EPS
- HITI N/A
- ACIU N/A
- Revenue
- HITI $398,202,371.00
- ACIU $32,014,254.00
- Revenue This Year
- HITI $12.43
- ACIU N/A
- Revenue Next Year
- HITI $11.39
- ACIU $533.21
- P/E Ratio
- HITI N/A
- ACIU N/A
- Revenue Growth
- HITI 9.22
- ACIU 91.20
- 52 Week Low
- HITI $1.57
- ACIU $1.43
- 52 Week High
- HITI $3.62
- ACIU $4.41
- Technical
- Relative Strength Index (RSI)
- HITI 39.78
- ACIU 51.75
- Support Level
- HITI $2.10
- ACIU $1.83
- Resistance Level
- HITI $2.35
- ACIU $2.10
- Average True Range (ATR)
- HITI 0.09
- ACIU 0.15
- MACD
- HITI -0.01
- ACIU -0.00
- Stochastic Oscillator
- HITI 32.76
- ACIU 44.44
About HITI High Tide Inc.
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, Famous Brandz, and others. The company's reportable operating segments are; Bricks and mortar which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada followed by the United States of America, and other international markets.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.